Deep Learning-Based Automated Assessment of Hepatic Fibrosis on Magnetic Resonance Images and Non-Image Data

Weixia Li,Yajing Zhu,Gangde Zhao,Xiaoyan Chen,Xiangtian Zhao,Haimin Xu,Yingyu Che,Yinan Chen,Ruokun Li,Yuxiang Ye,Xin Dou,Kemin Chen,Qing Xie,Fuhua Yan
DOI: https://doi.org/10.2139/ssrn.4128904
2022-01-01
SSRN Electronic Journal
Abstract:Background: To evaluate the performance of fully automated deep learning (DL) algorithm for staging hepatic fibrosis and distinguishing fibrosis from normal people based on MR images with or without non-image information.Methods: 500 patients were retrospectively enrolled from two hospitals. Model DL were built using delayed phase MR images to assess fibrosis stages. In addition, different models which combined model DL with non-image information including biomarkers (APRI and FIB-4), virus status (hepatitis B and C virus tests), and MR information (manufactures and static magnetic field) were built. The AUROCs were compared between different models using Delong test, the sensitivity and specificity of both model DL and model Full (model DL combined with all non-image information) were compared with experienced radiologists and biomarkers using McNemar’s test.Findings: In the test set, the AUROC (with 95% confidence intervals) values of model Full for diagnosing fibrosis stages F0-4, F1-4, F2-4, F3-4 and F4 were 0.99 (0.94-1.00), 0.98 (0.93-0.99), 0.90 (0.83-0.95), 0.81 (0.73-0.88) and 0.84 (0.76-0.90), respectively, which outperformed model DL on diagnosing F0-4 and F1-4. Compared with the radiologists, model Full showed better specificity for fibrosis stage F0-4, better sensitivity for the other four classification tasks. While compared with biomarkers, both model DL and model Full showed significantly higher specificity in staging F3-4 and F4.Interpretation: Deep learning-based model DL and model Full using delayed phase MR images provides a promising non-invasive assessment tool for the staging liver fibrosis with a performance superior to experienced radiologists and biomarkers (APRI and FIB-4) , which may be helpful to screen out CLD patients from normal individuals, instruct which patients need treatment and prevent patients from progressing to decompensated cirrhosis by paying more attention to patients with compensated cirrhosis (F4).Funding: This work was supported by the National Natural Science Foundation of China (grant numbers 81401406) and Innovative Research Team of High-level Local Universities in Shanghai. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscriptDeclaration of Interest: The authors declare that they have no conflict of interestEthical Approval: This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
What problem does this paper attempt to address?